Today’s a day where you could lose faith in modern healthcare startups.
Here’s four reasons to have hope.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A quartet of companies on Wednesday were selected among the 44 businesses that presented at MedCity INVEST, MedCity News’ healthcare investing conference this week in Chicago. The winning companies, honored as the Best of INVEST, are building breakthroughs that leverage breath tests to detect cancer or are building better tools to diagnose orthopedic injuries in the doctor’s office, among other things.
Investors from more than 60 healthcare funds attending INVEST helped select the winners, which were from four categories: diagnostics, medical devices, digital health and biopharma. A trio of judges reviewed the companies, then the remaining investors contributed a fourth “crowd” score: an average score from their ballots. Judges’ scores and the crowd score were averaged and the company with the highest score won its category.
The winners were:
- Breath Diagnostics (diagnostics category): A Louisville startup that offers breath analysis screening technology for early lung cancer detection.
- physIQ (digital health category): A Chicago company using machine learning technology to convert physiological data collected from wearables and implantable devices into actionable insight.
- Sparrow Pharmaceuticals (biopharma category): A Chicago company developing better corticosteroid drugs, as well as the first therapeutic antibody to treat PTSD.
- Trice Medical (medical device company): A Philadelphia company that has developed integrated camera-enabled needle technologies that provides orthopedic diagnoses in the doctor’s office. It has an FDA approved product and is expanding sales throughout the country.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
You will no doubt hear about these companies in the future because of new investment rounds, FDA approvals and other milestones. But we’ll also honor these four companies on MedCityNews.com, by celebrating their companies on a special section that will run through the rest of the year.
